Key takeaways
Atomoxetine (Strattera) and methamphetamine (Desoxyn) are both used to treat attention-deficit hyperactivity disorder (ADHD) in people 6 years and older, but they have some key differences. Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) and is not a controlled substance, meaning it has a lower risk of addiction and dependence. In contrast, methamphetamine is a stimulant and a Schedule II controlled substance, which means it has a higher risk of addiction and misuse. Atomoxetine can take a few weeks to show its full effects, while methamphetamine works more quickly. Methamphetamine is rarely prescribed due to its potential for serious side effects and addiction, whereas atomoxetine is considered a safer alternative but is not a first-choice option. Both medications can cause serious heart problems and mental health issues, but methamphetamine also carries risks like serotonin syndrome and worsening of motor and verbal tics. Atomoxetine is available as a generic, while methamphetamine is also available in generic form.
